Published in Medical Letter on the CDC and FDA, May 31st, 2009
Dr. Reardan has extensive experience in the arena of orphan drug development, having participated in more than 15 orphan drug designations in the United States and Europe resulting in 12...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA